嘉和生物通过港交所上市聆讯

金融界
Dec 04, 2025

观点网讯:12月3日,嘉和生物药业通过港交所聆讯。据招股书,嘉和生物主要从事肿瘤及自体免疫药物的开发及商业化,产品管线覆盖乳腺癌、肺癌及胃肠道肿瘤等全球前三大肿瘤靶标。观点新媒体了解到,2025年11月,嘉和生物向港交所再次递交上市申请,亿腾医药集团有限公司拟通过换股方式反向收购嘉和生物。交易完成后,公司将更名为“亿腾嘉和医药集团有限公司”,并将成为香港首宗依据《上市规则》第18A章的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10